Sanwa Kagaku Obtains Additional Approval For Miglitol
This article was originally published in PharmAsia News
Executive Summary
Sanwa Kagaku announced the company has obtained an additional indication for diabetic drug Seibule (miglitol), to be used in combination with insulin to lower glucose levels for patients who are less responsive to insulin alone. The company estimates the new addition will increase the drug's sales by 38 percent to ¥18 billion by March 2010, compared to estimated sales for March 2009. Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. (Click here for more - Japanese language